Brain

Roehri, Nicolas; Vulliemoz, Serge; Lagarde, Stanislas

doi: 10.1093/brain/awae164pmid: 38753681

Weiss, Shennan Aibel; Sperling, Michael R; Engel, Jerome; Staba, Richard

doi: 10.1093/brain/awae162pmid: 38758083

Shi, Wen; Eden, Uri; Kramer, Mark A; Chu, Catherine J

doi: 10.1093/brain/awae165pmid: 38753652

doi: 10.1093/brain/awae208pmid: 38941449

doi: 10.1093/brain/awae239pmid: 39023925

Husain, Masud

doi: 10.1093/brain/awae194pmid: 38978495

Gan-Or, Ziv

doi: 10.1093/brain/awae181pmid: 39087915

This scientific commentary refers to ‘Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson’s Disease Study’ by Westenberger et al. (https://doi.org/10.1093/brain/awae188) and ‘Parkinson’s disease variant detection and disclosure: PD GENEration, a North American study’ by Cook et al. (https://doi.org/10.1093/brain/awae142).

Wiech, Katja; Hartmann, Helena; Bingel, Ulrike

doi: 10.1093/brain/awae220pmid: 38987234

This scientific commentary refers to ‘How side effects can improve treatment efficacy: a randomized trial’ by Schenk et al. (https://doi.org/10.1093/brain/awae132).

Zhao, Meng; Lynch, David R; Irani, Sarosh R

doi: 10.1093/brain/awae236pmid: 39073761

This scientific commentary refers to ‘NMDA receptor autoantibodies primarily impair the extrasynaptic compartment’ by Jamet et al. (https://doi.org/10.1093/brain/awae163).

Mattsson-Carlgren, Niklas

doi: 10.1093/brain/awae237pmid: 39018494

This scientific commentary refers to ‘Towards cascading genetic risk in Alzheimer’s disease’ by Altmann et al. (https://doi.org/10.1093/brain/awae176).